CJC-1295 vs Tesamorelin · Mechanism, Dose, Cited Research

Side-by-side

	CJC-1295	Tesamorelin
Mechanism	Modified GHRH(1-29) with DAC; extended half-life.	44-amino-acid GHRH analog; preserves pulsatility; FDA-approved.
Half-life	~8 days (DAC variant).	Short plasma; pulsatile GH release on administration.
Dose	1-2 mg weekly SC.	1-2 mg daily SC (evening).
Cycle	12 weeks on / 4 off.	12 weeks on / 4 off (research); continuous in clinical use.
Research context	Research-grade; elevates IGF-1 baseline in volunteer studies¹.	FDA-approved; visceral fat reduction and metabolic endpoints in HIV lipodystrophy².
Cost tier	Mid (weekly dosing offsets per-mg cost).	High (daily dosing, higher per-cycle cost).

CJC-1295 and Tesamorelin are both GHRH analogs, but the comparison is between a research compound and an approved therapy. Tesamorelin is FDA-approved for HIV-associated visceral adiposity and has substantial clinical data on visceral fat reduction, liver fat reduction, and metabolic endpoints². CJC-1295 is a research compound with strong volunteer-study data but no clinical registration¹.

The pharmacokinetic difference shapes the research application. Tesamorelin preserves physiological GH pulsatility because each daily injection produces a bolus of GHRH activity that the pituitary responds to with a pulse, then returns to baseline. CJC-1295 with DAC maintains a persistent GHRH tone across its ~8-day half-life, which produces a more sustained elevation in baseline IGF-1. Researchers studying visceral adiposity or metabolic endpoints with an evidence-based comparator tend to select Tesamorelin. Researchers studying sustained IGF-1 elevation or working within a weekly-injection protocol select CJC-1295.

Dose frequency is the practical differentiator. Tesamorelin requires daily evening subcutaneous injection, which is the dosing regimen studied in the approval trials. CJC-1295 is dosed once to twice weekly. For a comparable GH output over time, the two compounds are roughly interchangeable in research protocols that do not demand the specific pharmacokinetic profile of either. See the full depth in Tesamorelin clinical history and GH secretagogue cycle design.

Frequently asked

Is Tesamorelin stronger than CJC-1295?

Tesamorelin has stronger clinical evidence because it is FDA-approved for HIV-associated visceral adiposity². CJC-1295 is a research compound with supportive but not regulatory-grade data. Direct head-to-head comparison on GH output magnitude is not available in the literature.

Why does Tesamorelin preserve pulsatility and CJC-1295 does not?

Tesamorelin is a conventional GHRH analog with a short half-life; each dose produces a pulse. CJC-1295 was engineered with a DAC extension specifically to create sustained GHRH tone over ~8 days, which is a different pharmacological design choice.

Can both be cycled the same way?

Yes in research protocols. The 12-weeks-on / 4-weeks-off pattern is applied to both compounds, though Tesamorelin in clinical use is often given continuously.

Research desk

Ordering both CJC-1295 and Tesamorelin for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.

Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. PMID: 16352683
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PMID: 18057338

All references verified against PubMed via NCBI E-utilities.